REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival

RRS at baseline and Week 12, and change in RRS, were significant predictors of both survival and clinical worsening-free survival. These data support the long-term predictive value of the RRS in a controlled study population.